Altre lingue Nabriva Therapeutics plc

Azioni

NBRVF

IE000OZRGNV6

Tempo differito OTC Markets Altri mercati azionari 17:34:09 25/04/2024			Variaz. 5gg	Var. 1 gen.
0,0001 ^USD	-.--%		-.--%	+9.900,00%

2023	Nabriva Therapeutics plc riporta i risultati degli utili per il secondo trimestre e i sei mesi conclusi il 30 giugno 2023	CI
2023	Sumitomo Pharma Co., Ltd. (TSE:4506) ha acquisito le attività e i diritti relativi alla lefamulina in Cina, Hong Kong, Macao e Taiwan da Nabriva Therapeutics plc (OTCPK:NBRV.F), Nabriva Therapeutics US, Inc, Nabriva Therapeutics GmbH e Nabriva Therapeutics Ireland Dac per 15 milioni di dollari.	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Nabriva Therapeutics plc Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	19/10/23
Nabriva Therapeutics plc(OTCPK:NBRV.F) dropped from NASDAQ Composite Index	31/07/23
Sumitomo Pharma Co., Ltd. acquired Assets and rights related lefamulin in China, Hong Kong, Macau and Taiwan from Nabriva Therapeutics plc (OTCPK:NBRV.F), Nabriva Therapeutics US, Inc, Nabriva Therapeutics GmbH and Nabriva Therapeutics Ireland Dac for $15 million.	31/07/23
Nabriva Therapeutics : Failure to Satisfy Listing Rule - Form 8-K	24/07/23
Arbutus Biopharma Promotes Dr. Karen Sims to Chief Medical Officer, Hires Christopher Naftzger as Chief Compliance Officer	10/07/23
Nabriva Therapeutics plc Appoints H. Michael Hogan as Chief Executive Officer	07/07/23
Nabriva Therapeutics plc Appoints Dave Maggio as Chief Financial Officer	07/07/23
Nabriva Therapeutics plc Reports Earnings Results for the First Quarter Ended March 31, 2023	22/05/23
NABRIVA THERAPEUTICS PLC MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)	17/04/23
Nabriva Therapeutics plc Reports Earnings Results for the Full Year Ended December 31, 2022	17/04/23
Nabriva Therapeutics plc Auditor Raises 'Going Concern' Doubt	17/04/23
Merck : fin de l'accord de distribution avec Nabriva	06/02/23
Nabriva Therapeutics : Material Agreement - Form 8-K	06/02/23
NABRIVA THERAPEUTICS PLC : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)	06/02/23
NABRIVA THERAPEUTICS PLC : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)	20/01/23
Nabriva Therapeutics plc Appoints Christopher Naftzger as Interim Chief Executive Officer	20/01/23
Nabriva Therapeutics : Termination of Material Agreement - Form 8-K	09/01/23
NABRIVA THERAPEUTICS PLC : Termination of a Material Definitive Agreement, Costs Associated with Exit or Disposal Activities, Other Events, Financial Statements and Exhibits (form 8-K)	09/01/23
Nabriva Therapeutics Provides Corporate Update	09/01/23
Health Care Up as Biogen Rises on Alzheimer's Drug Progress -- Health Care Roundup	06/01/23

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Nabriva Therapeutics plc

Azioni

NBRVF

IE000OZRGNV6

Altre lingue

Filtri